Personalis, Inc.

Personalis develops and commercializes genomic sequencing tests and laboratory services focused on cancer diagnostics and monitoring. The company's primary products include NeXT Personal, a tumor-informed liquid biopsy designed to detect minimal residual disease, monitor therapy response, and identify cancer recurrence in solid tumors; ImmunoID NeXT, a tissue-based service combining whole exome and whole transcriptome sequencing with analytics to characterize tumor composition and microenvironment; and NeXT Dx, a tumor profiling test intended to guide therapy selection and identify clinical trial opportunities. The company also offers NeXT Personal Dx for MRD detection.

Beyond its commercial testing services, Personalis operates a contract sequencing business providing whole exome and whole genome sequencing for pharmaceutical companies, diagnostic firms, research institutions, and government entities. This segment supports customers' translational research, biomarker discovery, drug development, and clinical trial activities. The company's customer base spans pharmaceutical and biopharmaceutical firms, diagnostics companies, universities, non-profits, government agencies, and individual patients.

Headquartered in Fremont, California, Personalis is incorporated in Delaware and trades on Nasdaq. The company maintains an international presence and serves the U.S. market as a primary revenue source. In 2022, the company entered a strategic collaboration with Tempus AI to expand access to ultra-sensitive recurrence testing for colorectal cancer patients.